- Conditions
- Mixed Connective Tissue Disease (MCTD), Systemic Lupus Erythematosus (SLE)
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 497
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lupus Nephritis, Proteinuria, Hematuria
- Interventions
- Velcade
- Drug
- Lead sponsor
- The Rogosin Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Efavaleukin Alfa, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 6
- States / cities
- Anniston, Alabama • Beverly Hills, California • Aventura, Florida + 3 more
- Conditions
- Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
- Interventions
- BIIB059 (litifilimab), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 53
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Biological · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,019 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 49
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 41 more
- Conditions
- Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
- Interventions
- Litifilimab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 62
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Deucravacitinib, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 39
- States / cities
- La Jolla, California • La Mesa, California • San Diego, California + 34 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- epratuzumab
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 10 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- DS-7011a, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Long Beach, California • San Antonio, Texas
- Conditions
- Lupus Erythematosus, Systemic, Lupus Nephritis
- Interventions
- rapcabtagene autoleucel
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Bernardino, California • San Francisco, California + 11 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- aspirin and meloxicam
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Not listed
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- RSLV-132, Placebo
- Drug
- Lead sponsor
- Resolve Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 16
- States / cities
- El Cajon, California • La Jolla, California • Los Alamitos, California + 13 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Project EVO Multi- Treatment
- Device
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19, Cell Therapy, Lupus, Lupus Nephritis (LN)
- Interventions
- CART19
- Biological
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 10 Years to 29 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lupus Nephritis (LN)
- Interventions
- C-CAR168
- Biological
- Lead sponsor
- AbelZeta Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
- Interventions
- Stem Cell Transplantation, CD34 selection
- Procedure · Device
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis, Lupus Glomerulonephritis
- Interventions
- Abetimus sodium (LJP 394)
- Drug
- Lead sponsor
- La Jolla Pharmaceutical Company
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2002
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 48 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- LY3361237, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 9
- States / cities
- Anniston, Alabama • Clearwater, Florida • Tampa, Florida + 6 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- ALX-0061, Placebo
- Biological
- Lead sponsor
- Ablynx, a Sanofi company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 24 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Levothyroxine
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Dry Eye Syndrome, Systemic Lupus Erythematosus
- Interventions
- ABBV-319
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- Avon Park, Florida • Clearwater, Florida • Margate, Florida + 4 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- GDC-0853
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 11
- States / cities
- Los Alamitos, California • Boca Raton, Florida • Brandon, Florida + 7 more